Table 4.
Response and remission rates compiled at 4–7-week follow-up (time frames vary over different studies).
| Author, Year | Substance | Scale | Response Rate (vs. Control) |
Remission Rate (vs. Control) |
|---|---|---|---|---|
| Griffiths, R. 2016 [41] | Psilocybin | GRID-HAMD-17 | 92% (vs. 32%) | 60% (vs. 16%) |
| Ross, S. 2016 [42] | Psilocybin | BDI | ~80% (vs. ~15%) | ~80% (vs. ~15%) |
| HADS Depression | ~70% (vs. ~40%) | ~70% (vs. ~40%) | ||
| Carhart-Harris, R. 2021 [43] | Psilocybin | QIDS-SR-16 | 70% (vs. 48%) [a] | 57% (vs. 28%) [a] |
| Daly, E.J. 2018 [26] | Esketamine | MADRS | 56% [b] | 42% [b] |
| Fedgchin, M. 2019 [34] | Esketamine | MADRS | 54.1% and 53.1% (vs. 38.9%) [c] | 36.0% and 38.8% (vs. 30.6%) [c] |
| Popova, V. 2019 [35] | Esketamine | MADRS | 69.3% (vs. 52.0%) | 52.5% (vs. 31.0%) |
| Ochs-Ross, R. 2020 [38] | Esketamine | MADRS | 27.0% (vs. 13.3%) | 17.5% (vs. 6.7%) |
| Ionescu, D.F. 2021 [40] | Esketamine | MADRS | 59% (vs. 48.0%) | 43.0% (vs. 27.0%) |
Clinical response was defined as ≥50% decrease in measure relative to baseline; symptom remission was defined as ≥50% decrease in measure relative to baseline and a score of ≤7 on GRID-HAMD-17, HADS D ≤ 7, BDI ≤ 12, or MADRS ≤ 10. [a] Control group was administered escitalopram instead of psilocybin. [b] After open label phase, where all participants received esketamine. [c] Results for esketamine 56, 84 mg, and placebo, respectively.